Physician profile

Gerald A Ross

Obstetrics & Gynecology · Port Saint Lucie, FL

NPI 1942295563

$449.54

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$122.55

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $122.55 2023 Veozah
Therapeuticsmd, INC. $92.64 2019
Exeltis, USA INC. $39.79 2019
Allergan, INC. $38.53 2019
Abbvie INC. $32.44 2019-2020
Amag Pharmaceuticals, INC. $27.94 2019-2020
Hologic Sales and Service, LLC $27.92 2019
Avion Pharmaceuticals $23.07 2019
Merck Sharp & Dohme LLC $19.79 2019
Teleflex LLC $13.38 2019
Bayer Healthcare Pharmaceuticals INC. $11.49 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gerald A Ross

$449.54

in general payments reported 2019-2025

Years
2019-2023
Top company
Astellas Pharma US INC

https://glasscript.com/doctor/133312/gerald-a-ross

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.